PACB
Pacific Biosciences of California
Pacific Biosciences of California historical holders
total: 4
Fairfax Financial Holdings Pacific Biosciences of California transactions over time
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2018 Q4
- Held for:
- 7 quarters
- Latest activity:
- 2020 Q3
Prem Watsa has been an institutional investor in Pacific Biosciences of California (PACB) since 2018 Q4. According to 2026 Q1 report, Prem Watsa doesn't hold any shares. The fund/company first acquired PACB in 2018 Q4, initially purchasing 160,000 shares. Since the initial investment, Fairfax Financial Holdings has made 1 more transaction in this position.
When did Prem Watsa exit their PACB position?
Prem Watsa no longer holds Pacific Biosciences of California (PACB). They sold off their entire position in 2020 Q3, closing out an investment that began in 2018 Q4.
When did Prem Watsa first invest in PACB?
Prem Watsa first invested in Pacific Biosciences of California (PACB) in 2018 Q4 at the reported quarter-end price of $7.39 per share, acquiring 160,000 shares in their initial purchase.
What is Prem Watsa's average cost basis for PACB?
Based on historical transaction data, Prem Watsa's estimated cost basis for Pacific Biosciences of California (PACB) is approximately $7.39 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $7.39
- Weighted AVG sell price:
- $3.44
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.